PFE or LLY: Which Is the Better Value Stock Right Now?

According to Zacks Research, Pfizer (PFE) is currently a better value stock than Eli Lilly (LLY). Pfizer has a Zacks Rank of #2 (Buy) compared to Eli Lilly's #3 (Hold), and boasts a Value grade of A versus Eli Lilly's C, driven by a lower forward P/E ratio of 7.57 compared to 32.57, a PEG ratio of 0.84 versus 1.04, and a P/B ratio of 1.45 versus 43.02.

Analysis

Pfizer (PFE) is presented as a more attractive value investment compared to Eli Lilly (LLY) within the Large Cap Pharmaceuticals sector, according to the provided Zacks Research analysis. This assessment is supported by Pfizer's Zacks Rank of #2 (Buy), indicating a stronger recent improvement in its earnings outlook than Eli Lilly, which holds a Zacks Rank of #3 (Hold). Further underscoring Pfizer's value proposition are its superior Style Score Value grade of 'A', contrasted with Eli Lilly's 'C'. Key fundamental metrics highlight this disparity: PFE trades at a forward P/E ratio of 7.57, significantly lower than LLY's 32.57. Additionally, PFE's PEG ratio of 0.84, which incorporates expected earnings growth, is more favorable than LLY's 1.04. The P/B ratio also points to PFE's relative undervaluation at 1.45, substantially below LLY's 43.02. These combined factors suggest that, based on traditional value metrics and earnings estimate trends, Pfizer currently offers a more compelling value opportunity. The per-ticker sentiment reinforces this, with PFE at a positive 0.8 and LLY at a negative -0.4.

Key Decisions for Investors

• Investors prioritizing value metrics in the Large Cap Pharmaceuticals sector should consider Pfizer (PFE) due to its #2 (Buy) Zacks Rank, 'A' Value grade, and significantly lower P/E, PEG, and P/B ratios compared to Eli Lilly.
• Eli Lilly (LLY) investors, particularly those focused on value, should note its #3 (Hold) Zacks Rank, 'C' Value grade, and higher valuation multiples, which may warrant a review of its position relative to peers like PFE.
• Given the stronger earnings outlook and more attractive valuation profile, PFE appears to be the superior option for investors seeking exposure to a fundamentally undervalued pharmaceutical stock at this time.